$2.33 Billion is the total value of SABBY MANAGEMENT, LLC's 252 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CUBIST PHARMACEUTICALS INCput | $421,015,000 | +9444.7% | 603 | 0.0% | 18.05% | +7208.1% | ||
| SYNAGEVA BIOPHARMA CORPput | $13,949,000 | +26.3% | 1,331 | 0.0% | 0.60% | -3.4% | ||
| ALEXZA PHARMACEUTICALS INCcall | $932,000 | +3.1% | 2,040 | 0.0% | 0.04% | -21.6% | ||
| PACIFIC ETHANOL INCput | $783,000 | -1.8% | 512 | 0.0% | 0.03% | -24.4% | ||
| DEPOMED INCcall | $766,000 | +643.7% | 551 | 0.0% | 0.03% | +450.0% | ||
| MEDICINES COput | $535,000 | +2.3% | 184 | 0.0% | 0.02% | -20.7% | ||
| ENANTA PHARMACEUTICALS INCcall | $440,000 | +7.8% | 102 | 0.0% | 0.02% | -17.4% | ||
| HORIZON PHARMA INCput | $346,000 | +4.5% | 219 | 0.0% | 0.02% | -21.1% | ||
| ADVAXIS INCput | $315,000 | +0.3% | 1,000 | 0.0% | 0.01% | -22.2% | ||
| GLMD | GALMED PHARMACEUTICALS LTD | $306,000 | -15.0% | 31,401 | 0.0% | 0.01% | -35.0% | |
| NEUROCRINE BIOSCIENCES INCput | $148,000 | -8.1% | 100 | 0.0% | 0.01% | -33.3% | ||
| TROV | TROVAGENE INC | $70,000 | -39.1% | 20,000 | 0.0% | 0.00% | -50.0% | |
| AGENUS INCput | $79,000 | +1.3% | 245 | 0.0% | 0.00% | -25.0% | ||
| BIODEL INCput | $39,000 | -22.0% | 182 | 0.0% | 0.00% | -33.3% | ||
| CVM | CEL-SCI CORP | $16,000 | -20.0% | 12,888 | 0.0% | 0.00% | 0.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SPDR S&P 500 ETF TRUST UNIT | 37 | Q3 2023 | 49.1% |
| ISHARES TR | 35 | Q3 2023 | 52.2% |
| SPDR S&P BIOTECHNOLOGY | 32 | Q3 2022 | 12.8% |
| AMARIN CORP PLC | 30 | Q4 2021 | 2.0% |
| BIOGEN INC | 24 | Q1 2021 | 26.2% |
| SAREPTA THERAPEUTICS INC | 24 | Q3 2020 | 4.6% |
| BIOGEN INC | 23 | Q1 2021 | 13.7% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2020 | 6.2% |
| BRAINSTORM CELL THERAPEUTICS INC | 21 | Q3 2023 | 1.6% |
| VERTEX PHARMACEUTICALS INC | 20 | Q1 2018 | 12.6% |
View SABBY MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| AGM GROUP HOLDINGS, INC. | January 10, 2023 | 627,936 | 2.6% |
| Bit Digital, Inc | January 10, 2023 | 3,166,917 | 3.8% |
| Cingulate Inc. | January 10, 2023 | 10 | 5.0% |
| Context Therapeutics Inc. | January 10, 2023 | 796,706 | 5.0% |
| HeartBeam, Inc. | January 10, 2023 | 271,788 | 3.4% |
| PharmaCyte Biotech, Inc. | January 10, 2023 | 934,456 | 5.0% |
| Rebus Holdings, Inc.Sold out | January 10, 2023 | 0 | 0.0% |
| TANTECH HOLDINGS LTD | January 10, 2023 | 41,500 | 0.6% |
| Quanergy Systems, Inc. | January 04, 2023 | 936,905 | 5.8% |
| TuanChe Ltd | January 04, 2023 | 2,384,713 | 10.0% |
View SABBY MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-04 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
| SC 13G | 2024-01-03 |
View SABBY MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.